152 related articles for article (PubMed ID: 15038472)
1. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
Edgar CM; Brunet DG; Fenton P; McBride EV; Green P
Can J Neurol Sci; 2004 Feb; 31(1):58-63. PubMed ID: 15038472
[TBL] [Abstract][Full Text] [Related]
2. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
[TBL] [Abstract][Full Text] [Related]
3. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
Soós N; Shakery K; Mrowietz U
Am J Clin Dermatol; 2004; 5(5):357-9. PubMed ID: 15554737
[TBL] [Abstract][Full Text] [Related]
4. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.
Drago F; Brusati C; Mancardi G; Murialdo A; Rebora A
Arch Dermatol; 1999 Oct; 135(10):1277-8. PubMed ID: 10522686
[No Abstract] [Full Text] [Related]
5. Contribution of endermology to improving indurations and panniculitis/lipoatrophy at glatiramer acetate injection site.
Rubio Fernández D; Rodríguez Del Canto C; Marcos Galán V; Falcón N; Edreira H; Sevane Fernández L; Francoli Martínez P; Sánchez-De la Rosa R
Adv Ther; 2012 Mar; 29(3):267-75. PubMed ID: 22382874
[TBL] [Abstract][Full Text] [Related]
6. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate.
Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R
Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757
[TBL] [Abstract][Full Text] [Related]
7. Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate.
Lebrun C; Mondot L; Bertagna M; Calleja A; Cohen M
Clin Neurol Neurosurg; 2011 Nov; 113(9):721-4. PubMed ID: 21839580
[TBL] [Abstract][Full Text] [Related]
8. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.
Hwang L; Orengo I
Cutis; 2001 Oct; 68(4):287-8. PubMed ID: 11710450
[No Abstract] [Full Text] [Related]
9. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
10. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
Ziemssen T; Neuhaus O; Hohlfeld R
Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
[TBL] [Abstract][Full Text] [Related]
11. Nicolau syndrome and localized panniculitis: a report of dual diagnoses with an emphasis on morphea profunda-like changes following injection with glatiramer acetate.
Mott SE; Peña ZG; Spain RI; White KP; Ehst BD
J Cutan Pathol; 2016 Nov; 43(11):1056-1061. PubMed ID: 27516414
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate in multiple sclerosis.
Mezzapesa DM; Rovaris M; Filippi M
Expert Rev Neurother; 2005 Jul; 5(4):451-8. PubMed ID: 16026228
[TBL] [Abstract][Full Text] [Related]
13. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
[TBL] [Abstract][Full Text] [Related]
14. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
Bains SN; Hsieh FH; Rensel MR; Radojicic C; Katz HT; Inamdar SR; Lang DM
Ann Allergy Asthma Immunol; 2010 Apr; 104(4):321-5. PubMed ID: 20408342
[TBL] [Abstract][Full Text] [Related]
16. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
[TBL] [Abstract][Full Text] [Related]
17. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
Wolinsky JS; Narayana PA; Johnson KP;
Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
[TBL] [Abstract][Full Text] [Related]
18. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months.
Fiore AP; Fragoso YD
Arq Neuropsiquiatr; 2005 Sep; 63(3B):738-40. PubMed ID: 16258646
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study.
Balak DM; Hengstman GJ; Hajdarbegovic E; van den Brule RJ; Hupperts RM; Thio HB
BMC Neurol; 2013 Oct; 13():146. PubMed ID: 24131589
[TBL] [Abstract][Full Text] [Related]
20. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
